key: cord-0765906-po4osmpj
authors: Machnicki, Stephen; Patel, Dhara; Singh, Anup; Talwar, Arunabh; Mina, Bushra; Oks, Margarita; Makkar, Priyanka; Naidich, David; Mehta, Atul; Hill, Nicholas; Brown, Kevin; Raoof, Suhail
title: The Utility of Chest CT imaging in suspected or diagnosed COVID-19 Patients – a review of literature
date: 2021-04-20
journal: Chest
DOI: 10.1016/j.chest.2021.04.004
sha: 2a3b57eecb6f11194a726d63437402ede9ae68da
doc_id: 765906
cord_uid: po4osmpj

The COVID-19 pandemic has had devastating medical and economic consequences globally. The severity of COVID-19 is related, in a large measure, to the extent of pulmonary involvement. The role of chest CT in the management of patients with COVID-19 has evolved since the onset of the pandemic. Specifically, the description of CT findings, use of CT chest in various acute and subacute settings and its usefulness in predicting chronic disease have been better defined. We performed a review of published data on CT scans in COVID-19 patients. A summary of the range of imaging findings, from typical to less common abnormalities is provided. Familiarity with these findings may facilitate in the diagnosis and management of this disease. A comparison of sensitivity and specificity of CT chest with RT-PCR testing highlights the potential role of CT imaging in difficult to diagnose cases of Covid-19. The utility of CT imaging to assess prognosis, guide management, and identify acute pulmonary complications associated with SARS-COV-2 is highlighted. Beyond the acute stage, it is important for clinicians to recognize pulmonary parenchymal abnormalities, progressive fibrotic lung disease and vascular changes that may be responsible for persistent respiratory symptoms. A large collection of multi institutional images has been included to elucidate the CT findings described.

The year 2020 will be remembered for the devastation caused by the coronavirus disease (COVID- 19) pandemic. There were intensive global efforts to mitigate its spread, produce vaccines, develop rapid and accurate diagnostics, and identify effective treatments. The key role of chest imaging has also evolved with the pandemic. Early in the pandemic, when molecular and antigenic testing were not as widely available, CT scanning provided results more rapidly, and in some circumstances, with greater sensitivity than reverse-transcription polymerase chain reaction (RT-PCR) for diagnosis of COVID-19. [1] [2] [3] [4] In April 2020, the Fleischner Society released a multinational expert consensus statement that offered guidance to physicians on the use of thoracic imaging in various healthcare environments. 5 The Society of Thoracic Radiology, the American College of Radiology, and the Radiological Society of North America offered additional guidance for the use of both plain chest radiography and computed tomography (CT) for patients suspected to have COVID-19. 6 These guidelines recommend against the routine use of chest CT to diagnose COVID-19, as J o u r n a l P r e -p r o o f findings were considered non-specific and a normal CT fails to rule out the infection. Additional concerns included the potential risk of aerosol dispersion of the virus during performance of the study, the time required to clean suites between patients and the need for personal protective equipment (PPE), placing additional strain on limited resources. 2 These recommendations are pragmatic and are based on valid clinical reasoning. In consonance with these guidelines, we do not recommend CT chest for routine diagnostic purposes or as a screening modality in asymptomatic individuals. CT chest may have utility in moderate to severe disease in patients who are demonstrating worsening gas exchange or showing lack of improvement in their respiratory status with time. This may apply to patients with a negative PCR test, but with a high index of clinical suspicion for COVID-19.

The purpose of this article is to review the data on COVID-19 published over the past year and put it in the context of the published guidelines. We focus on the role of CT scans in the diagnosis and management of patients with COVID-19 pneumonia. We reiterate the importance of standardizing descriptors of typical and atypical CT findings in COVID-19 pneumonia and discuss the role of chest CT in assessing severity of the disease and triaging the patient accordingly. Finally, we discuss the radiographic and clinical features that identify patients likely to develop progressive fibrotic lung disease.

We performed a systematic literature search using Embase, Medline, and WHO COVID-19 databases for papers published up to December 31 st 2020. There was an exception made by referencing an "ahead of print" article with accompanying editorial that came out in January 2021 and provides valuable information on long term (six months) follow up of pulmonary J o u r n a l P r e -p r o o f lesions. Tables of contents from specific radiology and cardiothoracic journals not included in   these databases were searched separately. Key search terms included Corona, Coronavirus, COVID-19, SARS-Cov-2, 2019nCoV, or Wuhan virus AND Computed tomography, Computerized tomography, CAT, CT, or HRCT. Study selection criteria included only articles in English, with COVID-19 patients confirmed by RT-PCR or gene sequencing. Studies were included only if a detailed description of chest CT imaging was included. Particular emphasis was given to metaanalyses. Conference abstracts, editorials, and case series with < 10 cases were excluded.

Duplicate studies -patients reported from the same hospital, during the same time frame, in different journals -were also excluded. Each of the 458 articles retrieved was graded from 1-6, utilizing a grading system by two members of the writing committee (either a pulmonologist or radiologist). Articles were assessed for number of patients studied, methodology, reproducibility, primary and secondary outcomes studied and clinical utility of recommendations made. A minimum cumulative average score of 60% had to be achieved to include the article. Any reviewer rejecting an article was asked to comment on the reasons for rejection. When there was significant disagreement between reviewers, a third senior member of the writing committee made the final decision.

There are a variety of diagnostic tests available for COVID-19, with Real-Time Polymerase Chain Reaction (RT-PCR) the reference standard. Rapid assay screening is only approximately 56% sensitive but 99.5% specific, with results available immediately. 7 The sensitivity and specificity of RT-PCR depends on site of swab collection and method of collection ( Table 1) . Accuracy of J o u r n a l P r e -p r o o f these tests varies by disease stage and degree of viral replication. Abnormal chest CT findings can precede positivity on RT-PCR, since the latter test may take up to 4 days to convert in a patient with COVID-19. 6 The reported sensitivities and specificities of CT for COVID-19 vary widely due to lack of strict diagnostic criteria for imaging in earlier studies. 8 However, the use of a standardized chest CT grading system can improve the diagnostic performance of CT chest (see below).

Patients referred for chest CT should undergo non-contrast enhanced imaging because most of the findings in non-complicated COVID-19 pneumonia are confined to the lungs, without involvement of the mediastinum or pleura. 9 Chest CT scan should be performed with an inspiratory breath-hold from the lung apices to the bases. Low-radiation-dose chest CT is preferred in order to minimize radiation burden. 2,10 Thin-section axial images with lung reconstruction algorithm should be produced. Intravenous contrast may be administered if CT pulmonary angiography is required to detect pulmonary embolism or if there is a concern for necrotizing pneumonia. 2, 9 COVID-19 lung disease may present with both typical and atypical CT findings. The Radiological Society of North America (RSNA) has provided guidance to standardize CT reporting in patients with COVID-19 pneumonia. The RSNA proposed four categories for reporting CT scan findings: typical, indeterminate, atypical, and negative ( Table 2) .

Typical features are the most specific for COVID-19 pneumonia and most characteristically include peripheral, bilateral, or multifocal rounded foci of ground glass attenuation (GGO).

Additional findings include: air-space consolidation, with or without an associated crazy-paving pattern and a reverse halo abnormality (Fig. 1a-c) . Indeterminate features include multifocal, J o u r n a l P r e -p r o o f diffuse, perihilar, or unilateral GGO, with or without consolidation, and air-space consolidation.

The latter often lacks a rounded configuration. These opacities may lack a peripheral distribution (Fig. 2 ).

An atypical appearance is uncommonly associated with COVID-19 pneumonia and is more indicative of an alternate diagnoses, including bacterial pneumonia with or without cavitation, and tree-in-bud branching centrilobular nodules. 6 The "indeterminate" pattern is mainly observed in elderly patients and is the most challenging. 11 In this category, the detection of subsegmental vascular enlargement (defined as more than 3 mm of diameter), involving both arteries and veins, is most frequently observed (p<0.001) and could be an ancillary sign to guide diagnosis. 11 Inui et al. utilized CT chest patterns described in the RSNA expert consensus statement and other CT grading systems, to calculate their sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for the diagnosis of COVID-19 (Table 3) . The presence of "typical appearance" on CT chest has a sensitivity and specificity of 73.5% and 82.8%, respectively. The presence of either "typical appearance" or "indeterminate appearance" on CT chest has a sensitivity and specificity of 92.0% and 41.0%, respectively. 12 Ciccarese, et al. reported that the application of the four standardized categories for CT reporting proposed by RSNA could support a faster triage of patients in the backdrop of high community disease burden and is highly predictive of RT-PCR-results. 11 In their series of 560 CT scans on 460 patients, the "typical" pattern provided a high PPV for COVID-19 (87.8%), while "atypical" and "negative" pattern provided a high PPV for non-COVID-19 (89.6% and 86.2%, respectively). 11 J o u r n a l P r e -p r o o f A separate COVID-19 Reporting and Data System (CO-RADS) score was proposed by the Dutch Radiological Society and can also be used for triaging suspected COVID-19 patients with moderate to severe symptoms. A CO-RADS score of 1 to 6 is useful to identify the likelihood of pulmonary involvement secondary to COVID-19 (Table 4 ) (Fig. 3a-e) . 13 CO-RADS score > 4 can be used to predict positive and negative PCR testing results in high prevalence settings, with a sensitivity of 89.4%, specificity of 87.2%, NPV of 94.6%, and PPV of 76.4%, respectively. 14 It should be pointed out that these reporting and scoring systems have been used mainly as research tools and are less commonly used in clinical practice. Their value in clinical settings remains to be established.

Chest CT may be utilized to stratify the severity of lung involvement and predict outcomes in COVID-19, which may in turn assist physicians in proper triaging of patients and allocation of resources. Studies have described five patterns of lung parenchymal involvement on CT scan that may correlate with no involvement to progression and severe disease. 4 These include no involvement, bronchopneumonia (Fig. 4a) , organizing pneumonia (Fig. 4b) , progressive organizing pneumonia (Fig. 4c) or diffuse alveolar damage patterns (Fig. 4d) . In a multivariate analysis, crazy paving (Fig. 5) , bronchial dilatation or bronchiectasis (Fig. 6) , and severity of parenchymal involvement (diffuse alveolar damage) may indicate a fibroproliferative process and may serve as independent predictors of poor outcome. 4, 15, 16 Specific segmental vascular changes on chest CT, like vascular thinning or enlargement (Fig. 7a) , vascular wall irregularity J o u r n a l P r e -p r o o f (Fig. 7b) ; vascular angulation ( Fig. 7c) , bronchovascular ectasia, and vascular annular contractions are other predictors of disease severity in cases of COVID-19 pneumonia. 17, 18 CO-RADS scores of 4 and 5 are suggestive of high and very high suspicion of pulmonary involvement, respectively, due to COVID-19. Hence, a CO-RADS score ≥4 can be used to put a patient in isolation or self-quarantine, while awaiting results of PCR testing. CT severity score (CTSS) is based on a subjective visual assessment of the extent of disease in each lobe of the lung. Presence of ground-glass, crazy-paving, and consolidation in each lobe is used for scoring. 19 Each lobe has a minimum score of 0 and maximum score of 5 (Table 5 ). 20 The total CTSS is the sum of the individual lobar scores and can range from 0 (no involvement) to 25 (maximum involvement). A CT severity score (CTSS) ≥10 and ≥15 (Fig. 8a-d) have a specificity of > 90% for hospital admission and ICU admission. A CTSS < 3 was found to be > 90% sensitive for patient discharge from the emergency department. 14 A CTSS of ≥17 is > 90% specific for 30-day mortality and a score < 5 predicts 30-day survival with a sensitivity of > 90%.

An example of the acute utility of chest CT is in patients with a high clinical suspicion of COVID-19 and moderate or severe illness with hypoxemia but in whom rapid antigen testing is negative. The typical chest CT findings enhance confidence in making the diagnosis and favor prompt initiation of steroids in these patients.

It has been proposed that modifications of ventilatory strategy can be based on the pattern of lung involvement on CT scan in COVID-19. 21 Patients requiring mechanical ventilation with focal or patchy abnormalities on CT chest may require less PEEP (Fig. 9a) than those with diffuse J o u r n a l P r e -p r o o f bilateral abnormalities on CT chest (Fig. 9b ) who may require high levels of PEEP, but there is little evidence to support this hypothesis so far. 21 

COVID-19 predisposes to both arterial and venous thrombosis. 2 22 Average time for diagnosis of PE is around 16 days after initial COVID-19 related symptoms. 22 It is worth noting that despite the higher incidence of PE in patients with COVID-19 pneumonia, evidence is lacking to support the utility of early CT angiograms without a clinical indication. 23 Microvascular thrombi may lead to severe physiological derangements but may not be detected by conventional contrast CT scans. COVID-19 may induce a strong inflammatory response with cytokine release, which may in turn culminate in vascular endothelial damage.

The net result is a hypercoagulable state and microvascular thrombosis. Autopsy reports have described vascular endothelial injury and widespread capillary microthrombi. 24, 25 Clinically, this may present as profound hypoxemia, very high d-dimer values, preserved lung compliance and increased physiological dead space. 26 Most patients will demonstrate multisystem organ J o u r n a l P r e -p r o o f dysfunction since this is a widespread phenomenon. 27 This entity is best detected by dual energy CT (DECT) (Fig. 11a,b) . 28 In a study by Remy-Jardin et al, 55 DECT scans performed in COVID-19 patients three months after hospital discharge, showed three interesting findings: a) unexpected proximal arterial thrombosis in 5.4% of patients b) disseminated lung perfusion abnormalities indicating microangiopathy in 65.5% of patients c) areas of increased perfusion corresponding to ground glass opacities from SARS-CoV-2 pneumonia. 29 Chest CT may be useful in patients with persistent or worsening hypoxia or fever. Multifocal ground glass opacities, airspace consolidation with air bronchograms +/-interlobular septal thickening or an "Atoll sign" or "reverse halo sign" (Fig. 12a,b) are patterns suggestive of organizing pneumonia (OP) which is discussed in the sub-acute/chronic section. Of note, 40.6% of patients with COVID-19 pneumonia who develop OP may demonstrate a more rapid evolution of opacities than are characteristic of OP. These patients may have acute fibrinous and organizing pneumonia. 4, 30 Patients may have non-resolving opacities with bronchoalveolar lavage (BAL) confirmation of eosinophilia, and subsequent resolution of symptoms and imaging findings with corticosteroid use. This may be suggestive of a chronic eosinophilic pneumonia pattern (CEP), and this has been reported in a few small case series in the setting of COVID-19 disease (Fig. 13a,b) . Patients with CT chest findings suggestive of OP or CEP may need bronchoscopy with BAL along with transbronchial biopsy to establish the diagnosis. These patients will need longer courses of steroids (perhaps months) compared to the usual 7 to 10day course given for COVID pneumonia.

Barotrauma, including pneumothorax (Fig. 14a) , pneumomediastinum (Fig. 14b) and pneumopericardium have been reported in the intubated COVID-19 cohort. In a large NYC hospital, there was a 24% rate of barotrauma in patients with COVID-19 pneumonia on mechanical ventilation; this was significantly higher than the 11% rate in the comparator group of intubated patients without COVID-19 infection as well as historical controls. 31 The most common event was pneumomediastinum followed by pneumothorax. Increased barotrauma events did not lead to increased overall mortality. 31 Longer hospital length of stay and younger age were associated with a higher incidence of barotrauma events. 31

Worsening gas exchange, increasing PEEP and tidal volume requirements (thus increasing driving pressures) are the most likely etiologies of ventilator induced lung injury (VILI), but this has not been definitively correlated. Prolonged mechanical ventilation from COVID-19 or associated conditions, can also lead to ventilator induced lung injury. Notably, increased prevalence of barotrauma has been previously reported in MERS and SARS.

CT scans may also provide clues to clinicians about the underlying cardiac injury in hospitalized COVID-19 patients, particularly pericardial effusion that has been reported to occur in up to 5% of patients. 2 Pericardial effusion may be related to the severity of myocardial inflammation and occurs with higher incidence in those with severe illness. 32, 33 Another feature of myocardial injury may be the development of left ventricular failure and pulmonary edema.

Not infrequently, patients with COVID pneumonia develop superimposed bacterial or fungal infections. New or worsening fevers, increases in leukocyte and neutrophil counts, sputum cultures, and elevated procalcitonin may be helpful in making such a determination, but repeat imaging including chest CT is often helpful. Focal opacities, lobar consolidation, centrilobular tree-in-bud opacities, and pleural effusions are more commonly seen in bacterial pneumonia as compared to COVID-19. 34 In patients who have been treated with immunosuppressants such as steroids or cytokine (IL-1 and IL-6) inhibitors, not only bacterial, but also fungal and mycobacterial infections should be considered. This is especially so if cavitary lung disease is seen (Fig. 15 ). With steroid treatment in patients from endemic areas, helminthic infestations may occur as well. 34

Most studies on the temporal course of chest imaging changes after COVID-19 pneumonia have examined short time intervals (30 days or so) (Fig. 16) . In one study, chest CT scan was performed on the day before discharge, two weeks, and four weeks after discharge. 35 The authors reported that in 64.7% of these discharged patients, the CT scan changes fully resolved after 4 weeks. Among discharged patients, those with more than 3 lobes involved on CT scan, and CT scores >4 at week 2 after symptom onset, persistent chest imaging abnormalities were more likely. 30 As the disease progresses, increases in number, extent, and density of GGO on CT is observed and these may evolve into consolidation and crazy paving lesions in days to weeks (Fig. 17) . 36, 37 J o u r n a l P r e -p r o o f Chen et al. reported that older patients were more likely to develop reticular opacities (a possible sign of fibrosis) than younger patients. 38 In a retrospective study of COVID-19 with 3 months of follow up, patients who had residual pulmonary parenchymal disease on CT scan had had higher rates of previous MICU admission, longer hospital stays, more extensive disease on initial CT scan and more underlying comorbidities (Fig. 18a,b) . 39 The most common abnormal radiological features in patients demonstrating residual disease were GGO (54%), followed by mixed GGO and sub-parenchymal bands (31.8%) and pure subpleural bands (13.7%) (Fig. 19a,b) . These may represent early fibrotic changes (Fig. 20a,b) .

In a recent prospective study, Han et al reported 114 patients who underwent chest CT during their initial hospital admission and then again six months later. 40 pneumonia. The role of anti-fibrotics and lung transplantation in this group of patients remains to be studied.

Four to 10% patients with COIVD pneumonia may develop an "atoll" or "reverse halo" sign, suggestive of histopathologic organizing pneumonia. 42, 43 Consistent with other forms of acute lung injury, patients may develop linear opacities, worsening reticulation, subpleural curvilinear bands and bronchial dilatation suggestive of histopathologic fibrosis (Fig. 21) . 42 

Preexisting interstitial lung disease is a risk factor for poor outcomes from COVID-19. 44 In one study, patients with interstitial lung disease who contracted COVID-19 had a greater than fourfold increase in the adjusted odds of death and were more likely to require ICU admission. 45 Over the years, there has been increasing appreciation of the role of viruses in acute exacerbations of underlying ILD (Fig. 22a-d) . 46 The optimum management of such chronic lung sequela of COVID-19 infection is unknown. The role of corticosteroids, other immunosuppressive agents, or antifibrotic agents in symptomatic J o u r n a l P r e -p r o o f patients with residual fibrotic changes post COVID-19 pneumonia remains to be formally studied.

There are anecdotal reports of successful lung transplantation for non-resolving Acute Respiratory Distress Syndrome (ARDS) following COVID-19. Pathology findings on the explanted lung were similar to irreversible end-stage pulmonary fibrosis (Fig. 23) . 47 Lung transplantation is a consideration in patients surviving COVID-19 pneumonia who develop severe pulmonary fibrosis and are appropriate candidates.

Since the onset of the pandemic, the role of chest imaging has considerably evolved. The purpose of this report, therefore, has been to review all available, pertinent reports from 2020, assessing both current and potential indications for CT. In particular, this includes evaluating the sensitivity and specificity of CT compared to other testing modalities, as well as in the specific settings of acute vs subacute and chronic disease.

Importantly, utilization of a standardized chest CT reporting system based on consensus appearances of typical and atypical findings has been shown to aid in the triage of emergency room patients. In the acute setting, chest CT also may be utilized to stratify the severity of lung involvement, assist in the determination of the need for hospitalization and/or ICU admission, and predict outcomes in COVID-19. Chest CT may also be useful in patients with persistent or worsening hypoxia, with the ability to differentiate non-COVID-19 lung abnormalities, in J o u r n a l P r e -p r o o f particular, organizing pneumonia, chronic eosinophilic pneumonia, and barotrauma. In the appropriate clinical setting CTA is also valuable to diagnose pulmonary embolism. In the subacute and chronic settings, CT scan can potentially help predict which patients are likely to have residual pulmonary involvement, including the development of pulmonary fibrosis-like abnormalities.

Future directions for research include the need for continued validation of standardized reporting systems for patients suspected of having COVID-19 and determination of the range of inter-and intra-observer variability which will require larger studies. Similarly, continued evaluation of the diagnostic accuracy of CT is also necessary. The role of CT will need to be reassessed as different strains of COVID-19 emerge, with different rates of infectivity and morbidity and mortality. Finally, it is to be expected that artificial intelligence will likely play an ever larger role in CT assessment of a range of COVID-19 related issues.

J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f 

CT findings of 795 COVID-19 positive cases: a multicenter study in Egypt

Chest CT in COVID-19: What the Radiologist Needs to Know

Diagnostic Yield of Computed Tomography for the Identification of Coronavirus Disease 2019 Using Repeated Reverse Transcriptase Polymerase Chain Reaction Testing or Confirmed True-Negative State as Reference Standard: Systematic Review and Meta-Analysis

A Pattern Categorization of CT Findings to Predict Outcome of COVID-19 Pneumonia

The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society

Radiological Society of North America Expert Consensus Document on Reporting Chest CT Findings Related to COVID-19: Endorsed by the Society of Thoracic Radiology, the American College of Radiology, and RSNA. Radiology: Cardiothoracic Imaging

Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection

Thoracic imaging tests for the diagnosis of COVID-19

Variations in CT Utilization, Protocols, and Radiation Doses in COVID-19 Pneumonia: Results from 28 Countries in the IAEA Study

Accuracy and Reproducibility of Low-Dose Submillisievert Chest CT for the Diagnosis of COVID-19

Diagnostic Accuracy of North America Expert Consensus Statement on Reporting CT Findings in Patients Suspected of Having COVID-19 Infection: An Italian Single-Center Experience

Comparison of Chest CT Grading Systems in Coronavirus Disease 2019 (COVID-19) Pneumonia. Radiology: Cardiothoracic Imaging

CO-RADS: A Categorical CT Assessment Scheme for Patients Suspected of Having COVID-19-Definition and Evaluation

Chest CT in COVID-19 at the ED: Validation of the COVID-19 Reporting and Data System (CO-RADS) and CT Severity Score: A Prospective, Multicenter, Observational Study

Can CT performed in the early disease phase predict outcome of patients with COVID 19 pneumonia? Analysis of a cohort of 64 patients from Germany

Chest Computed Tomography Scoring in Patients With Novel Coronavirus-infected Pneumonia: Correlation With Clinical and Laboratory Features and Disease Outcome

A new imaging sign in COVID-19 pneumonia: vascular changes and their correlation with clinical severity of the disease

Pulmonary Vascular Manifestations of COVID-19 Pneumonia

Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosis

Pulmonary sequelae in convalescent patients after severe acute respiratory syndrome: evaluation with thin-section CT

Management of COVID-19 Respiratory Distress

CT imaging of pulmonary embolism in patients with COVID-19 pneumonia: a retrospective analysis

Low Detection Rate of Pulmonary Embolism in Patients Presenting to the Emergency Department With Suspected Coronavirus Disease 2019 (COVID-19): A Single-Centre UK Study

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

Endothelial cell infection and endotheliitis in COVID-19

Anatomical and Pathological Observation and Analysis of SARS and COVID-19: Microthrombosis Is the Main Cause of Death

Hyperthrombotic Milieu in COVID-19 Patients

COVID-19 Infection: Viral Macroand Micro-Vascular Coagulopathy and Thromboembolism/Prophylactic and Therapeutic Management

Assessment of pulmonary arterial circulation 3 months after hospitalization for SARS-CoV-2 pneumonia: Dual-energy CT (DECT) angiographic study in 55 patients

Organizing pneumonia of COVID-19: Time-dependent evolution and outcome in CT findings

Increased Incidence of Barotrauma in Patients with COVID-19 on Invasive Mechanical Ventilation

Cardiac manifestations of COVID-19 in Shenzhen

Cardiovascular manifestations in severe and critical patients with COVID-19

Differential diagnosis between the coronavirus disease 2019 and Streptococcus pneumoniae pneumonia by thin-slice CT features

Chest Computed Tomography and Clinical Follow-Up of Discharged Patients with COVID-19 in Wenzhou City

Temporal Changes of CT Findings in 90 Patients with COVID-19 Pneumonia: A Longitudinal Study

Chest CT Findings in Coronavirus Disease-19 (COVID-19): Relationship to Duration of Infection

Temporal lung changes in high-resolution chest computed tomography for coronavirus disease 2019

Chest CT in COVID-19 pneumonia: what are the findings in mid-term follow-up?

Six-Month Follow-up Chest CT findings after Severe COVID-19 Pneumonia

Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy

Computed Tomography Features of Coronavirus Disease 2019 (COVID-19): A Review for Radiologists

CT Features and Short-term Prognosis of COVID-19 Pneumonia: A Single-Center Study from Kashan, Iran. Radiology: Cardiothoracic Imaging

Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study

Increased Odds of Death for Patients with Interstitial Lung Disease and COVID-19: A Case-Control Study

The contribution of infection and the respiratory microbiome in acute exacerbations of idiopathic pulmonary fibrosis

Lung transplantation for patients with severe COVID-19

Interpreting a covid-19 test result

Chest CT in COVID-19 pneumonia: A review of current knowledge

Time Course of Lung Changes at Chest CT during Recovery from Coronavirus Disease 2019 (COVID-19)